Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives
Standard
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. / Kretschmer, Alexander; van den Bergh, Roderick C N; Martini, Alberto; Marra, Giancarlo; Valerio, Massimo; Tsaur, Igor; Heidegger, Isabel; Kasivisvanathan, Veeru; Kesch, Claudia; Preisser, Felix; Fankhauser, Christian D; Zattoni, Fabio; Ceci, Francesco; Olivier, Jonathan; Chiu, Peter; Puche-Sanz, Ignacio; Thibault, Constance; Gandaglia, Giorgio; Tilki, Derya; EAU-YAU Prostate Cancer Working Group.
in: CANCERS, Jahrgang 14, Nr. 1, 147, 2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives
AU - Kretschmer, Alexander
AU - van den Bergh, Roderick C N
AU - Martini, Alberto
AU - Marra, Giancarlo
AU - Valerio, Massimo
AU - Tsaur, Igor
AU - Heidegger, Isabel
AU - Kasivisvanathan, Veeru
AU - Kesch, Claudia
AU - Preisser, Felix
AU - Fankhauser, Christian D
AU - Zattoni, Fabio
AU - Ceci, Francesco
AU - Olivier, Jonathan
AU - Chiu, Peter
AU - Puche-Sanz, Ignacio
AU - Thibault, Constance
AU - Gandaglia, Giorgio
AU - Tilki, Derya
AU - EAU-YAU Prostate Cancer Working Group
PY - 2022
Y1 - 2022
N2 - With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.
AB - With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.
U2 - 10.3390/cancers14010147
DO - 10.3390/cancers14010147
M3 - SCORING: Review article
C2 - 35008310
VL - 14
JO - CANCERS
JF - CANCERS
SN - 2072-6694
IS - 1
M1 - 147
ER -